NeuroPace (NPCE) Free Cash Flow Growth (1y) (2021 - 2026)
NeuroPace (NPCE) Free Cash Flow Growth (1y) (2021 - 2026) Analysis & Trends
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | FCF Growth (1y) (Qtr) |
|---|---|---|---|---|---|
| 1 | Abbott Laboratories | 198.70 Bn | 193.10 Bn | 7.27 Bn | 28.87% |
| 2 | Stryker | 125.85 Bn | 122.37 Bn | 4.50 Bn | 14.12% |
| 3 | Medtronic | 118.44 Bn | 109.22 Bn | 6.41 Bn | 0.77% |
| 4 | Boston Scientific | 72.64 Bn | 72.10 Bn | 3.85 Bn | 13.29% |
| 5 | Edwards Lifesciences | 51.94 Bn | 47.69 Bn | 1.35 Bn | 142.84% |
| 6 | Dexcom | 34.48 Bn | 32.53 Bn | 830.00 Mn | -11.68% |
| 7 | GE HealthCare Technologies | 33.60 Bn | 31.49 Bn | 2.18 Bn | 750.00% |
| 8 | Koninklijke Philips | 26.30 Bn | 22.98 Bn | 4.55 Bn | 0.40% |
| 9 | Steris | 23.00 Bn | 22.52 Bn | 684.20 Mn | -14.34% |
| 10 | NeuroPace | 479.51 Mn | 427.81 Mn | 18.91 Mn | -86.14% |
Historic Data
Download Data| Date | Value |
|---|---|
| Jun 30, 2026 | -86.14% |
| Mar 31, 2026 | 20.17% |
| Dec 31, 2025 | 109.05% |
| Sep 30, 2025 | -4.81% |
| Jun 30, 2025 | 44.65% |
| Mar 31, 2025 | 0.24% |
| Dec 31, 2024 | -33.61% |
| Sep 30, 2024 | 18.93% |
| Jun 30, 2024 | 8.22% |
| Mar 31, 2024 | 23.14% |
| Dec 31, 2023 | 58.22% |
| Sep 30, 2023 | 66.81% |
| Jun 30, 2023 | 60.48% |
| Mar 31, 2023 | 14.01% |
| Dec 31, 2022 | 6.05% |
| Sep 30, 2022 | -55.67% |
| Jun 30, 2022 | -82.55% |
| Mar 31, 2022 | -93.75% |
| Dec 31, 2021 | -31.20% |
| Sep 30, 2021 | 16.99% |